sevoflurane has been researched along with 2019 Novel Coronavirus Disease in 7 studies
Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.
sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was designed to evaluate the feasibility and safety of sedation with inhaled sevoflurane in combination with intravenous esketamine during PP in patients with COVID-19-ARDS (CARDS)." | 1.72 | Sevoflurane in combination with esketamine is an effective sedation regimen in COVID-19 patients enabling assisted spontaneous breathing even during prone positioning. ( Bansbach, J; Heinrich, S; Kalbhenn, J; Kaufmann, K; Wenz, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 7 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansbach, J | 1 |
| Wenz, J | 1 |
| Kaufmann, K | 1 |
| Heinrich, S | 1 |
| Kalbhenn, J | 1 |
| Reins, J | 1 |
| Balling, F | 1 |
| Baader, C | 1 |
| Böck, E | 1 |
| Schöniger, W | 1 |
| van Erp, R | 1 |
| Eff, S | 1 |
| Hafner, S | 1 |
| Orser, BA | 1 |
| Wang, DS | 1 |
| Lu, WY | 1 |
| Nieuwenhuijs-Moeke, GJ | 1 |
| Jainandunsing, JS | 1 |
| Struys, MMRF | 1 |
| Jerath, A | 1 |
| Ferguson, ND | 1 |
| Cuthbertson, B | 1 |
| Kaura, V | 1 |
| Hopkins, PM | 1 |
| Coppola, S | 1 |
| Cenci, S | 1 |
| Cozzolino, M | 1 |
| Chiumello, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| AnaConDa-therapy in COVID-19 Patients[NCT05586126] | 42 participants (Actual) | Observational | 2020-10-01 | Terminated (stopped due to Concerns about possible association between drug and increased ICU mortality) | |||
| A Phase 3, Multicenter, Randomized, Controlled, Open Label, Assessor-Blinded Study to Evaluate the Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensi[NCT05327296] | Phase 3 | 235 participants (Anticipated) | Interventional | 2022-06-30 | Recruiting | ||
| A Phase 3, Multicenter, Randomized, Controlled, Open Label, Assessor-Blinded Study to Evaluate the Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensi[NCT05312385] | Phase 3 | 235 participants (Anticipated) | Interventional | 2022-04-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sevoflurane and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.
Topics: Algorithms; Anesthetics, Inhalation; Anesthetics, Intravenous; Betacoronavirus; Coronavirus Infectio | 2020 |
6 other studies available for sevoflurane and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Sevoflurane in combination with esketamine is an effective sedation regimen in COVID-19 patients enabling assisted spontaneous breathing even during prone positioning.
Topics: Cohort Studies; COVID-19; Humans; Ketamine; Prone Position; Respiration, Artificial; Sevoflurane | 2022 |
[Nephrogenic diabetes insipidus after inhalation sedation with sevoflurane in a patient with COVID-19-associated acute respiratory distress syndrome].
Topics: Anesthetics, Inhalation; COVID-19; Diabetes Insipidus, Nephrogenic; Diabetes Mellitus; Humans; Pneum | 2023 |
Sedating ventilated COVID-19 patients with inhalational anesthetic drugs.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pilot Projects; Pneumonia, Vir | 2020 |
Sevoflurane, a sigh of relief in COVID-19?
Topics: Anesthetics, Inhalation; Conscious Sedation; Coronavirus Infections; COVID-19; Humans; Pandemics; Pn | 2020 |
Sevoflurane may not be a complete sigh of relief in COVID-19.
Topics: Anesthetics, Inhalation; Coronavirus Infections; COVID-19; Critical Care; Genetic Predisposition to | 2020 |
Sevoflurane sedation and nephrogenic diabetes insipidus in patients affected with severe acute respiratory syndrome coronavirus 2.
Topics: Anesthesia; Anesthetics, Inhalation; COVID-19; Diabetes Insipidus, Nephrogenic; Humans; Hypnotics an | 2021 |